Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis

被引:2
|
作者
Zhou, Yi-Xin [1 ]
Hu, Qian-Cheng [2 ]
Zhu, Ya-Juan [1 ]
Mu, Xiao-Li [1 ]
Liu, Ji-Yan [1 ]
Chen, Ye [3 ]
机构
[1] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, 37 Guoxue Xiang St, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Gastr Canc Ctr, Lab Gastr Canc,Div Med Oncol,Canc Ctr, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Canc Ctr, Div Abdominal Tumor Multimodal Treatment,Dept Radi, 37 Guoxue Xiang St, Chengdu 610041, Sichuan, Peoples R China
关键词
Muscle-invasive bladder cancer; Trimodality therapy; Radical cystectomy; Neoadjuvant chemotherapy; LONG-TERM OUTCOMES; QUALITY-OF-LIFE; UROTHELIAL CARCINOMA; ADJUVANT ATEZOLIZUMAB; MODALITY THERAPY; ELDERLY-PATIENTS; PHASE-III; RADIOTHERAPY; MULTICENTER; IMVIGOR010;
D O I
10.1186/s40001-023-01408-9
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background:Trimodality therapy (TMT) is a mature alternative to radical cystectomy (RC) for patients with muscle-invasive bladder cancer (MIBC) who seek to preserve their primary bladder or are inoperable due to comorbidities. To date, there has been increasing evidence of the effectiveness of TMT as an alternative to RC. In contrast, no literature has stated the effectiveness of neoadjuvant chemotherapy combined with RC (NAC + RC) compared with TMT. Objective:We aimed to compare the prognosis between patients receiving TMT and NAC + RC. Methods:The clinicopathological characteristics of patients with T2-4aN0M0 MIBC were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate Cox proportional hazards regression models and Kaplan-Meier survival curves were used for the survival analysis. Propensity-score matching (PSM) was applied to determine the differences between the two groups. The primary outcome was cancer-specific survival (CSS), and the secondary outcome was overall survival (OS). Results:In total, 1,175 patients with MIBC who underwent TMT (n = 822) or NAC + RC (n = 353) were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. After 1:1 PSM, the final patient sample included 303 pairs. The prognosis of patients receiving NAC + RC was significantly better than that of patients receiving TMT in both unmatched and matched cohorts (5-year CSS: before PSM, 75.4% vs. 50.6%, P < 0.0001; after PSM, 76.3% vs. 49.5%, P < 0.0001; 5-year OS: before PSM, 71.7% vs. 37.4%, P < 0.0001; after PSM, 71.7% vs. 31.4%, P < 0.0001). The survival advantages of NAC + RC remained remarkable in the stratified analysis of most factors after PSM. Multivariate Cox regression analysis showed that being older than 68 years old, unmarried, grade III/IV, T3-4a stage, and undergoing TMT independently correlated with poor OS. Conclusion:Thus, in this study, patients with MIBC receiving NAC + RC presented with a better prognosis than those receiving TMT.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer
    Fahmy, Omar
    Khairul-Asri, Mohd Ghani
    Schubert, Tina
    Renninger, Markus
    Malek, Rohan
    Kuebler, Hubert
    Stenzl, Arnulf
    Gakis, Georgios
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (02) : 43 - 53
  • [32] Neoadjuvant chemotherapy with gemcitabine plus carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer
    Ohyama, Chikara
    Hatakeyama, Shingo
    Yoneyama, Takahiro
    Koie, Takuya
    INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (01) : 3 - 4
  • [33] Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer
    Macleod, Liam C.
    Fam, Mina M.
    Yabes, Jonathan G.
    Hale, Nathan E.
    Turner, Robert M., II
    Lopa, Samia H.
    Gingrich, Jeffrey R.
    Borza, Tudor
    Skolarus, Ted A.
    Davies, Benjamin J.
    Jacobs, Bruce L.
    CLINICAL GENITOURINARY CANCER, 2020, 18 (03) : 201 - +
  • [34] COST-EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY REGIMENS PRIOR TO RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER
    Joyce, Daniel D.
    Wymer, Kevin M.
    Sharma, Vidit
    Moriarty, James P.
    Borah, Bijan J.
    Geynisman, Daniel M.
    Plimack, Elizabeth R.
    Costello, Brian A.
    Pagliaro, Lance C.
    Boorjian, Stephen A.
    JOURNAL OF UROLOGY, 2022, 207 (05): : E670 - E671
  • [35] Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer
    Milowsky, Matthew I.
    Stadler, Walter M.
    Bajorin, Dean F.
    BJU INTERNATIONAL, 2008, 102 (09) : 1339 - 1344
  • [36] Population-based outcome of muscle-invasive bladder cancer following radical cystectomy: who can benefit from adjuvant chemotherapy?
    Tian, Junjie
    Sun, Junjie
    Fu, Guanghou
    Xu, Zhijie
    Chen, Xiaoyi
    Shi, Yue
    Jin, Baiye
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (01)
  • [37] Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer
    Johnson, Skyler B.
    Yu, James B.
    CURRENT ONCOLOGY REPORTS, 2018, 20 (09)
  • [38] Trimodality Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer
    Chen, Ronald C.
    Shipley, William U.
    Efstathiou, Jason A.
    Zietman, Anthony L.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (08): : 952 - 960
  • [39] Bladder Preserving Trimodality Therapy for Muscle-Invasive Bladder Cancer
    Skyler B. Johnson
    James B. Yu
    Current Oncology Reports, 2018, 20
  • [40] The impact of cigarette smoking on response rate and survival in patients with muscle-invasive bladder cancer undergoing neoadjuvant chemotherapy and radical cystectomy
    Krauter, J.
    Laukhtina, E.
    Shariat, S. F.
    EUROPEAN UROLOGY, 2024, 85 : S1966 - S1966